Skip to main content
Figure 3 | Breast Cancer Research

Figure 3

From: A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis

Figure 3

CMTC and the prediction of benefits of ET in ER+ breast cancer. Kaplan-Meier analysis was used to compare patients' relapse-free survival (A) between ET treatment and no treatment (B) among all 756 ER+ breast cancers, (C) between the three CMTC groups of all 756 ER+ breast cancers and ET treatment vs no treatment in 299 CMTC-1-only ER+ cancers and (D) and ET treatment vs no treatment between 457 CMTC-2- and CMTC-3-only ER+ cancers. The P values were determined using the log-rank test. CMTC = ClinicoMolecular Triad Classification; ER = estrogen receptor; ET = endocrine therapy; TN = triple-negative.

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us